Literature DB >> 15979264

Excipient effects on gastrointestinal transit and drug absorption in beagle dogs.

Julia D R Schulze1, Erin E Peters, Ann W Vickers, J Scott Staton, Mark D Coffin, Gary E Parsons, Abdul W Basit.   

Abstract

Previous work has shown that polyethylene glycol 400 (PEG 400) has an accelerating effect on gastrointestinal transit and a modulating influence on drug absorption in humans. The aim of this study was to assess the impact of various excipients, PEG 400, propylene glycol, d-alpha-tocopheryl-polyethylene glycol-1000 succinate (TPGS) and Labrasol on gastrointestinal transit and drug absorption in four beagle dogs using scintigraphy. Each dog received, on five separate occasions, water (control) or a dose of excipient equivalent to 1 g PEG 400, 2 g propylene glycol, 1 g TPGS or 2 g Labrasol dissolved in water and administered in the form of two capsules. The model drugs ampicillin (200mg) and antipyrine (100mg) were co-administered in the capsules. The capsule solutions were radiolabelled with technetium-99m to follow their transit using a dual-headed gamma camera, and blood samples were collected to determine drug pharmacokinetics. On a separate occasion, the drugs were dissolved in saline and given intravenously. The capsules rapidly disintegrated in the stomach liberating their liquid contents. The mean small intestinal transit times for the different treatments (control, PEG 400, propylene glycol, TPGS and Labarasol) were 183, 179, 195, 168 and 154 min, respectively. The corresponding mean absolute oral bioavailability figures were 36, 32, 39, 42 and 32% for ampicillin and 76, 74, 85, 73 and 74% for antipyrine, respectively. The transit and bioavailability data for the excipient treatments were not significantly different from the control. In summary, these excipients, at the doses administered, have limited influence on gastrointestinal transit and drug in beagle dogs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15979264     DOI: 10.1016/j.ijpharm.2005.05.004

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

Review 1.  Challenges and opportunities in achieving bioequivalence for fixed-dose combination products.

Authors:  Amitava Mitra; Yunhui Wu
Journal:  AAPS J       Date:  2012-06-09       Impact factor: 4.009

Review 2.  Impact of excipient interactions on drug bioavailability from solid dosage forms.

Authors:  Ravikiran Panakanti; Ajit S Narang
Journal:  Pharm Res       Date:  2012-05-19       Impact factor: 4.200

Review 3.  Safety and Biopharmaceutical Challenges of Excipients in Off-Label Pediatric Formulations.

Authors:  Anteneh Belayneh; Ebisa Tadese; Fantahun Molla
Journal:  Int J Gen Med       Date:  2020-11-09

4.  Evaluation of the clearance of a sublingual buprenorphine spray in the beagle dog using gamma scintigraphy.

Authors:  Fiona McInnes; Nicola Clear; Gerry James; Howard N E Stevens; Unai Vivanco; Michael Humphrey
Journal:  Pharm Res       Date:  2007-09-01       Impact factor: 4.200

5.  In vivo performance of an oral MR matrix tablet formulation in the beagle dog in the fed and fasted state: assessment of mechanical weakness.

Authors:  Fiona McInnes; Nicola Clear; Michael Humphrey; Howard N E Stevens
Journal:  Pharm Res       Date:  2007-10-05       Impact factor: 4.200

6.  Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females.

Authors:  Diane A I Ashiru; Rajesh Patel; Abdul W Basit
Journal:  Pharm Res       Date:  2008-07-04       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.